United Therapeutics Corp D
D
UTHR
307.51
USD
-4.94
(-1.58%)
مغلق
حجم التداول
11,231
الربح لكل سهم
28
العائد الربحي
-
P/E
13
حجم السوق
13,810,943,549
الأخبار المقالات
العنوان: United Therapeutics Corp
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.